Current challenges in treating MRSA: what are the options? (Q37291338)

19 August 2017

1 reference

title

Current challenges in treating MRSA: what are the options? (English)

1 reference

19 August 2017

2

Peter M Hawkey

1 reference

19 August 2017

Natasha V D V Ratnaraja

series ordinal

1

1 reference

PubMed ID

18847401

19 August 2017

language of work or name

1 reference

1 October 2008

1 reference

Expert Review of Anti-infective Therapy

19 August 2017

1 reference

19 August 2017

6

1 reference

19 August 2017

5

1 reference

19 August 2017

601-618

1 reference

Molecular epidemiology of clinically significant antibiotic resistance genes

19 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Prospective comparison of methicillin-susceptible and methicillin-resistant community-associated Staphylococcus aureus infections in hospitalized patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Etiology and treatment of community-associated methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Three-year surveillance of community-acquired Staphylococcus aureus infections in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Epidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Community-associated MRSA (CA-MRSA): an emerging pathogen in infective endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Proposed definitions of community-associated meticillin-resistant Staphylococcus aureus (CA-MRSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Community-associated methicillin-resistant Staphylococcus aureus isolates causing healthcare-associated infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Multiple cases of familial transmission of community-acquired methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Risk factors for community-associated methicillin-resistant Staphylococcus aureus skin infections among HIV-positive men who have sex with men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Comparative molecular analysis of community- or hospital-acquired methicillin-resistant Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Comparison of both clinical features and mortality risk associated with bacteremia due to community-acquired methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Staphylococcal cassette chromosome mec (SCCmec) typing of methicillin-resistant Staphylococcus aureus strains isolated in 11 Asian countries: a proposal for a new nomenclature for SCCmec elements

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

The molecular evolution of methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

International clones of methicillin-resistant Staphylococcus aureus in two hospitals in Miami, Florida

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Molecular techniques for MRSA typing: current issues and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Prevalence of SCCmec type IV in nosocomial bloodstream isolates of methicillin-resistant Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

The emergence and importation of diverse genotypes of methicillin-resistant Staphylococcus aureus (MRSA) harboring the Panton-Valentine leukocidin gene (pvl) reveal that pvl is a poor marker for community-acquired MRSA strains in Ireland

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Polyclonal emergence and importation of community-acquired methicillin-resistant Staphylococcus aureus strains harbouring Panton-Valentine leucocidin genes in Belgium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Staphylococcal cassette chromosome mec and Panton-Valentine leukocidin characterization of methicillin-resistant Staphylococcus aureus clones

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

High diversity of Panton-Valentine leukocidin-positive, methicillin-susceptible isolates of Staphylococcus aureus and implications for the evolution of community-associated methicillin-resistant S. aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Epidemic community-associated methicillin-resistant Staphylococcus aureus: recent clonal expansion and diversification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

The role of virulence determinants in community-associated MRSA pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

The arginine catabolic mobile element and staphylococcal chromosomal cassette mec linkage: convergence of virulence and resistance in the USA300 clone of methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Community-adapted methicillin-resistant Staphylococcus aureus (MRSA): population dynamics of an expanding community reservoir of MRSA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Methicillin-resistant Staphylococcus aureus disease in three communities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Clinical practice: colonization, fomites, and virulence: rethinking the pathogenesis of community-associated methicillin-resistant Staphylococcus aureus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

High frequencies of clindamycin and tetracycline resistance in methicillin-resistant Staphylococcus aureus pulsed-field type USA300 isolates collected at a Boston ambulatory health center

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Guidelines for the control and prevention of meticillin-resistant Staphylococcus aureus (MRSA) in healthcare facilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Vaccine assembly from surface proteins of Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Use of a conjugate polysaccharide vaccine in the prevention of invasive staphylococcal disease: is an additional vaccine needed or possible?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Guidelines for the laboratory diagnosis and susceptibility testing of methicillin-resistant Staphylococcus aureus (MRSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

The problem with glycopeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Vancomycin-intermediate Staphylococcus aureus with phenotypic susceptibility to methicillin in a patient with recurrent bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Linezolid in vitro: mechanism and antibacterial spectrum

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Efficacy of linezolid versus comparator therapies in Gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Treatment of hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Pharmacodynamics of antibiotics to treat multidrug-resistant Gram-positive hospital infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Linezolid in postneurosurgical infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Multiresistant-MRSA tricuspid valve infective endocarditis with ancient osteomyelitis locus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Successful treatment of MRSA native valve endocarditis with oral linezolid therapy: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

In vitro susceptibilities of zygomycetes to conventional and new antifungals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Registered and Investigational Drugs for the Treatment of Methicillin-Resistant Staphylococcus aureus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Treatment of infections caused by resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

New antimicrobial agents as therapy for resistant gram-positive cocci

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

New antimicrobial agents for the treatment of Gram-positive bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Central venous catheter colonization by linezolid-resistant, vancomycin-susceptible Enterococcus faecalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Biological counterstrike: antibiotic resistance mechanisms of Gram-positive cocci

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Linezolid resistance in clinical isolates of Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

The need for new therapeutic agents: what is the pipeline?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Daptomycin Dose-Effect Relationship against Resistant Gram-Positive Organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Daptomycin for treatment of patients with bone and joint infections: a systematic review of the clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Treatment challenges in the management of complicated skin and soft-tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Use of daptomycin to treat drug-resistant Gram-positive bone and joint infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Comparative bactericidal activities of daptomycin and vancomycin against glycopeptide-intermediate Staphylococcus aureus (GISA) and heterogeneous GISA isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Tigecycline: what is it, and where should it be used?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Tigecycline: a single antibiotic for polymicrobial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Tigecycline: in-vitro performance as a predictor of clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Antibiotics for treatment of resistant gram-positive coccal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744].

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Tigecycline is efficacious in the treatment of complicated intra-abdominal infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

In vitro activities of tigecycline combined with other antimicrobials against multiresistant gram-positive and gram-negative pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Clinical profile of ceftobiprole, a novel beta-lactam antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Ceftobiprole: in-vivo profile of a bactericidal cephalosporin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Pharmacokinetic and pharmacodynamic profile of ceftobiprole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

MRSA--the tip of the iceberg

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Can beta-lactams be re-engineered to beat MRSA?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

In vivo pharmacodynamic activity of the glycopeptide dalbavancin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Dalbavancin, a long-acting lipoglycopeptide for the treatment of multidrug-resistant Gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Taking inventory: antibacterial agents currently at or beyond phase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Pharmacodynamics of Oritavancin (LY333328) in a Neutropenic-Mouse Thigh Model of Staphylococcus aureus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Telavancin: a new lipoglycopeptide with multiple mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

In vitro activity of the novel diaminopyrimidine, iclaprim, in combination with folate inhibitors and other antimicrobials with different mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Antipneumococcal and antistaphylococcal activities of ranbezolid (RBX 7644), a new oxazolidinone, compared to those of other agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Antianaerobe activity of RBX 7644 (ranbezolid), a new oxazolidinone, compared with those of eight other agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Oxazolidinones: activity, mode of action, and mechanism of resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

In vitro activity of RBx 7644 (ranbezolid) on biofilm producing bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

CS-023 (R-115685), a novel carbapenem with enhanced in vitro activity against oxacillin-resistant staphylococci and Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

Linezolid therapy for infective endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.601

21 January 2018

Identifiers

DOI

10.1586/14787210.6.5.601

1 reference

19 August 2017

1 reference

PubMed ID

18847401